Description
Amphastar Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products. The Company’s generic product candidates at various development stages that leverage its various technical capabilities, including injectable technologies, including various delivery methods and sizes of pre-filled syringes, vials in solution, suspension and lyophilized forms; inhalation technologies, including metered dose inhalers (MDIs) and metered dose inhalers (DPIs); and analytical technologies. As of May 20, 2014, the Company manufactures and sells 15 products in the United States and is developing a portfolio of 13 generic and seven injectable and inhalation product candidates. In addition to its marketed products, it has a pipeline of 20 generic and product candidates in various stages of development which target a variety of indications.
Key stats and ratios
| Q2 (Jun '14) | 2013 | |
| Net profit margin | -2.41% | 5.16% |
| Operating margin | -2.39% | 7.61% |
| EBITD margin | - | 13.36% |
| Return on average assets | -1.28% | 3.55% |
| Return on average equity | -1.76% | 4.89% |
| Employees | 1,217 |
No comments:
Post a Comment